Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer.
A prospective randomized trial for metastatic prostatic cancer in 220 patients who were refractory to hormone therapy was conducted by the National Prostatic Cancer Project from 1984 to 1985. As of July, 1986, the evaluation of these patients reflected no difference in response to either estramustine phosphate (Emcyt) or flutamide. Toxicities were minimal, and the observed survival and progression-free survival intervals were noteworthy in view of the overall prospects for such patients. Future studies dealing with specific quality of life issues seem to be indicated by our results.
de Kernion
J N
JN
Division of Urology, University of California, Los Angeles.
Murphy
G P
GP
Priore
R
R
D000813:Anilides / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004961:Estramustine / Q000009:adverse effects / Q000627:therapeutic use*; D005485:Flutamide / Q000009:adverse effects / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D009325:Nausea / Q000139:chemically induced; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011897:Random Allocation; D014839:Vomiting / Q000139:chemically induced
D000813:Anilides; D009588:Nitrogen Mustard Compounds; D004961:Estramustine; D005485:Flutamide